** Shares of drug developer Arvinas ARVN.O fall 3.4% to $8.70
** Brokerage Leerink lowers PT to $12 from $49, maintains "outperform" rating
** Despite disappointing topline results for vepdegestrant, staying the course and remaining outperform pending detailed data release and visibility on a number of key value levers - Leerink
** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug, failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last week
** It is too early to assume that vepdeg is inferior to elacestrant, as the failure in the intention-to-treat population could have been driven by a number of factors - brokerage
** Elacestrant is used to treat certain types of hormone receptor-positive breast cancer
** As of last close, ARVN down 53% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。